Press Releases

70% of patients surveyed reported the burden of chemotherapy treatment was almost as great as the burden of the disease itself, and 71% would prefer not to receive it again Findings indicate that...

Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment...

Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now...

Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., March 20, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai's...